18 November 2022>: Original Paper
Altered Serum Bile Acid Profile Associated with Chronic Allograft Dysfunction in Kidney Transplant Recipients
Yamei Li 1ACDE , Hua Zhang 23CFG , Xinhua Dai 1BC , Yunfei An 1BD , Yi Li 1AD , Lin Yan 1EF , Yunying Shi 4EF , Jiwen Fan 1BC , Xingxin Gong 1BDF , Lei Zhang 1D , Yuangao Zou 1F , Lanlan Wang 1AG , Yangjuan Bai 1ADE*DOI: 10.12659/AOT.937974
Ann Transplant 2022; 27:e937974
Table 2 Serum BAs subgroup concentrations and ratios in HCs and KTRs with different allograft function.
HC | STA | CAD1 | CAD2 | P | |
---|---|---|---|---|---|
15 BAs (ng/mL) | 1311.9 (864.5–1715.6) | 1370.4 (950.5–2200.2) | 1505.4 (1072.2–2706.1) | 1044.5 (673.0–1866.3) | 0.126 |
Unconj.BAs (ng/mL) | 465.9 (257.9–777.3) | 333.6 (164.0–581.0) | 360.3 (182.5–778.9) | 127.1 (75.6–324.2)* | 0.002 |
Conj.BAs (ng/mL) | 748.2 (448.9–1006.2) | 960.1 (612.3–1691.4) | 1137.6 (650.4–2008.5)* | 855.5 (571.5–1465.0) | 0.026 |
G-conj.BAs (ng/mL) | 670.6 (392.6–940.5) | 860.7 (574.0–1514.8) | 918.4 (568.0–1743.1) | 653.3 (444.8–1210.3) | 0.031 |
T-conj.BAs (ng/mL) | 57.0 (36.0–88.7) | 80.0 (43.6–180.1) | 139.2 (52.8–207.1)* | 144.8 (94.5–286.2)* | 0.001 |
PBAs (ng/mL) | 845.2 (449.4–1228.4) | 1012.9 (652.8–1584.5) | 1298.3 (778.7–2122.5)* | 877.1 (488.9–1623.1) | 0.034 |
Unconj.PBAs (ng/mL) | 238.2 (95.3–443.2) | 188.7 (97.5–408.3) | 238.1 (96.2–653.7) | 87.8 (41.9–266.3)& | 0.031 |
Conj.PBAs (ng/mL) | 538.0 (322.9–784.8) | 829.7 (454.8–(1381.4)* | 897.0 (536.3–1622.9)* | 762.7 (421.7–1211.4) | 0.006 |
G-conj.PBAs (ng/mL) | 483.9 (287.0–716.2) | 737.9 (416.9–1198.5)* | 755.7 (481.2–1436.1)* | 598.3 (326.3–952.2) | 0.009 |
T-conj.PBAs (ng/mL) | 44.1 (29.9–72.3) | 73.0 (39.0–163.4)* | 130.2 (47.7–177.8)* | 137.6 (82.9–248.0)* | |
SBAs (ng/mL) | 403.6 (252.8–536.7) | 312.2 (193.9–484.2) | 300.9 (120.6–475.2) | 171.0 (73.8–359.5)* | 0.008 |
Unconj.SBAs (ng/mL) | 173.9 (124.0–312.8) | 121.6 (61.4–205.0)* | 110.8 (49.5–207.2) | 36.7 (20.4–92.9)* | |
Conj.SBAs (ng/mL) | 165.3 (107.9–232.3) | 178.5 (104.6–286.1) | 134.2 (73.4–284.4) | 104.1 (45.6–253.6) | 0.324 |
G-conj.SBAs (ng/mL) | 157.9 (94.5–219.9) | 171.3 (93.5–277.5) | 128.1 (70.8–278.3) | 93.1 (42.2–238.4) | 0.298 |
T-conj.SBAs (ng/mL) | 8.7 (5.1–16.2) | 7.8 (3.6–14.4) | 6.5 (3.1–12.8) | 7.5 (2.9–19.6) | 0.675 |
SBAs/PBAs | 0.48 (0.35–0.68) | 0.30 (0.14–0.47)* | 0.22 (0.10–0.40)* | 0.20 (0.11–0.28)* | |
Conj./Unconj.BAs | 1.85 (0.84–2.65) | 3.07 (1.79–5.57)* | 2.70 (1.12–6.12) | 5.64 (2.97–10.93)* | |
CA/CDCA | 0.34 (0.24–0.63) | 0.25 (0.14–0.37) | 0.44 (0.18–0.76) | 0.45 (0.24–0.85)# | 0.017 |
DCA/CA | 2.00 (0.42–4.70) | 0.20 (0.04–2.75)* | 0.06 (0.01–0.61)* | 0.06 (0.20–0.58)* | |
LCA/CDCA | 0.03 (0.01–0.10) | 0.03 (0.008–0.08) | 0.01 (0.004–0.03)* | 0.02 (0.006–0.03) | 0.013 |
TCA/CA | 0.15 (0.06–0.45) | 0.45 (0.16–0.85)* | 0.31 (0.08–1.26) | 1.07 (0.73–6.26)* | |
GCA/CA | 1.74 (0.85–4.30) | 4.20 (1.95–7.92)* | 2.29 (0.92–7.92) | 4.70 (3.56–15.92)* | 0.002 |
TCDCA/CDCA | 0.23 (0.11–0.66) | 0.43 (0.18–0.86) | 0.44 (0.17–1.20) | 1.75 (0.91–3.34)* | |
GCDCA/CDCA | 2.76 (1.14–5.12) | 3.69 (1.82–7.83) | 3.30 (1.38–6.57) | 7.51 (3.44–14.04)* | 0.011 |
GDCA/DCA | 0.58 (0.37–0.99) | 1.01 (0.48–1.85)* | 0.69 (0.37–1.59) | 0.96 (0.47–1.77) | 0.045 |
TDCA/DCA | 0.07 (0.03–0.15) | 0.15 (0.07–0.36)* | 0.19 (0.08–0.38)* | 0.36 (0.15–0.52)* | |
GLCA/LCA | 0.71 (0.39–1.14) | 0.37 (0.23–0.90)* | 0.38 (0.15–0.70)* | 0.28 (0.00–0.43)* | |
TLCA/LCA | 0.04 (0.02–0.08) | 0.03 (0.01–0.05) | 0.02 (0.01–0.07) | 0.03 (0.02–0.08) | 0.010 |
G-unconj. – glycine unconjugated; T-conj. – taurine-conjugated; * # & |